INCY - Incyte Corporation
| Previous Close | 65.03 |
| Open | 64.86 |
| Bid | 63.00 x 800 |
| Ask | 71.00 x 900 |
| Day's Range | 64.33 - 66.90 |
| 52 Week Range | 58.33 - 106.95 |
| Volume | 894,897 |
| Avg. Volume | 1,493,687 |
| Market Cap | 14.154B |
| Beta (3Y Monthly) | 1.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.49 |
| Earnings Date | Feb 13, 2019 - Feb 18, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 84.00 |
- Zacks•4 days ago
Merck's Keytruda Improves Survival in Esophageal Cancer Study
Merck's (MRK) Keytruda meets primary endpoint of overall survival in a phase III study evaluating it for the second-line treatment of advanced esophageal cancer.
Markit•4 days agoSee what the IHS Markit Score report has to say about Incyte Corp.
Incyte Corp NASDAQ/NGS:INCY
Markit•11 days agoSee what the IHS Markit Score report has to say about Incyte Corp.
Incyte Corp NASDAQ/NGS:INCY
- Business Wire•12 days ago
Incyte to Present at Upcoming Investor Conference
Incyte Corporation announced today that it will present at Evercore ISI HEALTHCONx on Wednesday, November 28, 2018 at 3:30 pm EST in Boston.
Market Realist•13 days agoHow Wall Street Analysts View Exelixis
Exelixis (EXEL) reported net income of $126.6 million in the third quarter compared to $81.4 million in the third quarter of 2017. The company’s net income over the first nine months of this year amounted to $330.0 million compared to $115.7 million in the same period the prior year.
- GlobeNewswire•14 days ago
Factors of Influence in 2018, Key Indicators and Opportunity within Molson Coors Brewing, Coca-Cola European Partners, Brinker International, Incyte, RPC, and Group 1 Automotive — New Research Emphasizes Economic Growth
NEW YORK, Nov. 05, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Motley Fool•17 days ago
Incyte's Shares Have Taken a Beating in 2018 -- Here's Why
Here's what we can learn from the failure of Incyte's highly-touted cancer therapy.
- Motley Fool•17 days ago
Scary Markets, Frightening Stocks, and How to Keep From Panicking
Here's what you need to know to keep your cool in terrifying times.
- Thomson Reuters StreetEvents•18 days ago
Edited Transcript of INCY earnings conference call or presentation 30-Oct-18 12:00pm GMT
Q3 2018 Incyte Corp Earnings Call
- Business Wire•18 days ago
Multiple Abstracts Highlighting Data from Incyte’s Targeted Therapy Portfolio Accepted for Presentation at the 60th Annual ASH Meeting
Results of REACH1 trial evaluating ruxolitinib in patients with steroid-refractory acute graft-versus-host disease accepted as an oral presentation
InvestorPlace•18 days ago3 Big Stock Charts for Thursday: Walmart, Prologis and Incyte
Gilead Sciences (NASDAQ:GILD) fell 5.4% after UnitedHealth Group (NYSE:UNH) unveiled a new plan that favors lower-cost HIV treatments, putting Gilead’s core business in the crosshairs. Rather, investors may want to take a closer look at Walmart (NYSE:WMT), Prologis (NYSE:PLD) and Incyte (NASDAQ:INCY). Walmart has been one of the market’s bigger winners since June, up more than 20% in that short timeframe.
- ACCESSWIRE•18 days ago
Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Incyte
NEW YORK, NY / ACCESSWIRE / November 1, 2018 / U.S. equities rose on Wednesday as a number of high profile companies reported upbeat corporate earnings that helped boost investor confidence. The Dow Jones ...
- Market Realist•20 days ago
Why Incyte’s Q3 2018 Earnings Beat Revenue Estimates
Incyte (INCY) released its Q3 2018 earnings today. The company beat Wall Street analysts’ estimates for revenue but missed estimates for EPS. It reported EPS of $0.14 on revenues of $449.68 million in the third quarter of 2018, compared to estimates for EPS of $0.40 on revenues of $449.20 million.
Motley Fool•20 days agoIncyte Corp (INCY) Q3 2018 Earnings Conference Call Transcript
INCY earnings call for the period ending September 30, 2018.
- Zacks•20 days ago
Incyte (INCY) Misses on Q3 Earnings & Revenues, Updates View
Incyte (INCY) third-quarter earnings and revenues miss estimates but rise year over year.
- Zacks•20 days ago
Incyte (INCY) Misses Q3 Earnings and Revenue Estimates
Incyte (INCY) delivered earnings and revenue surprises of -5.00% and -3.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•20 days ago
Incyte: 3Q Earnings Snapshot
On a per-share basis, the Wilmington, Delaware-based company said it had profit of 14 cents. Earnings, adjusted for stock option expense and non-recurring costs, were 38 cents per share. The results fell ...
- Business Wire•20 days ago
Incyte Reports 2018 Third Quarter and Nine Month Financial Results and Provides Updates on Key Clinical Programs
WILMINGTON, Del.-- -- Total product-related revenues of $430 million for the three months and $1.2 billion for the nine months ended September 30, 2018; Jakafi ® revenues of $348 million in 3Q 2018 and $1.0 billion YTD 2018 sNDA for ruxolitinib for the treatment of patients with steroid-refractory acute graft versus host disease accepted by the FDA for Priority Review Compelling data from pemigatinib ...
- Motley Fool•22 days ago
Better Buy: Vertex Pharmaceuticals Incorporated vs. Incyte Corporation
Which stock wins in a matchup between these two biotechs?
- Market Realist•24 days ago
What Analysts Recommend for Incyte ahead of Q3 Earnings
Wall Street analysts estimate Incyte’s (INCY) revenues will increase by ~17.7% to $449.2 million during the third quarter of 2018 compared to revenues of $381.5 million during the third quarter of 2017. Also, the earnings per share are estimated to be $0.40 for the third quarter of 2018 as compared to earnings per share of $0.08 for the third quarter of 2017. Incyte stock has fallen nearly 46.6% over the last 12 months and decreased by ~35.7% in 2018 year-to-date.
- Market Realist•24 days ago
Analysts Expect Incyte to Report Revenue Growth in Third Quarter
As discussed earlier, analysts estimate Incyte (INCY) to report growth of 17.7% in its revenues to $449.2 million during the third quarter of 2018. The below graph compares the revenues of Incyte since the first quarter of 2017 and estimates for the third quarter of 2018. Incyte’s revenue stream includes product sales, royalty revenues, and other revenues from collaborations. Incyte acquired the commercial rights for Iclusig from Ariad Pharmaceuticals in 2016.
- Business Wire•25 days ago
Incyte Named a 2018 Top Employer by Science Magazine
Incyte Corporation (INCY) announced today that it has been named one of the global biotechnology and pharmaceutical industry’s top employers by Science magazine, ranking second on the list of only 20 companies recognized in the publication’s annual Top Employer’s Survey. “We are proud to be recognized as the number two top employer in the biopharma industry by Science magazine and, importantly, also by our own team,” said Hervé Hoppenot, Chief Executive Officer, Incyte. The Science and Science Careers’ 2018 annual Top Employers Survey polled employees in biotechnology, pharmaceutical and related industries to determine the 20 best employers in these industries as well as their driving characteristics.
Markit•25 days agoSee what the IHS Markit Score report has to say about Incyte Corp.
Incyte Corp NASDAQ/NGS:INCY
- Business Wire•25 days ago
FDA Grants Priority Review for Ruxolitinib (Jakafi®) as a Treatment for Patients with Acute Graft-Versus-Host Disease
Incyte Corporation (INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its supplemental New Drug Application (sNDA) for ruxolitinib (Jakafi®) for the treatment of patients with acute graft-versus-host-disease (GVHD) who have had an inadequate response to corticosteroids. The FDA grants Priority Review to medicines that have the potential to provide significant improvements in the treatment of a serious disease. This designation shortens the FDA review period to six months compared to 10 months for Standard Review.
